Dallas Ebola Patient Receives Experimental Drug

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

DALLAS — The Liberian man battling Ebola at a Dallas hospital is now receiving an experimental drug that could save his life.

It’s called brincidofovir. The biopharmaceutical company Chimerix got approval from the FDA for emergency use on Thomas Eric Duncan on Friday. Duncan is currently in critical but stable condition at Texas Presbyterian Hospital in Dallas.

The experimental antiviral drug was being developed to treat life-threatening viruses including smallpox. But antiviral drugs can be used to treat a wide variety of diseases.

RELATED – Coming Clean: Family Moved from Ebola-Infected Apartment

This is the same drug that was originally denied to Josh Hardy, a 7-year-old who was treated for cancer and then developed an adenovirus that nearly killed him. In March, his parents launched a social media campaign to get the medicine, and it drew national attention. Josh then received the drug and recovered.

Fort Worth Dr. Kent Brantly and two other American missionaries received other experimental drugs — ZMapp, which is not out of supply, and TKM-Ebola. In all three cases, the drugs saved their lives.

Hopefully, brincidofovir will work another miracle.